Nello Mainolfi, Chief Executive Officer at Kymera Therapeutics, Inc. (KYMR), sold 60,000 shares at $61.46 ($3.7M) on 2025-10-29, disclosed to the SEC on 2025-10-29.
Scheduled sale ($3.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $59.72 | 1,862 | $111K | 3.0% |
| 2 | $59.72 | 1,862 | $111K | 3.0% |
| 3 | $61.02 | 24,511 | $1.5M | 40.9% |
| 4 | $61.02 | 24,511 | $1.5M | 40.9% |
| 5 | $61.46 | 3,627 | $223K | 6.1% |
| 6 | $61.46 | 3,627 |
| $223K |
| 6.1% |
| Total | $60.99 avg | 60,000 | $3.7M | 100% |
| Filing → |
| KYMR | SELL | 2026-07-02 | $9.2M | — | Filing → |
| KYMR | SELL | 2026-04-29 | $2.4M | — | Filing → |
| KYMR | SELL | 2026-02-25 | $2.7M | — | Filing → |